Verve Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2021 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Verve Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2021 to Q1 2024.
  • Verve Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $22.7M, a 1016% increase year-over-year.
  • Verve Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $213M, a 35.4% decline from 2022.
  • Verve Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $329M, a 12.8% decline from 2021.
  • Verve Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $377M, a 307% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $22.7M +$20.7M +1016% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q1 2023 $2.04M +$1.53M +304% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 $505K -$93.3M -99.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q1 2021 $93.8M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.